Literature DB >> 1755097

Review and update: oncogenic osteomalacia-rickets.

N Weidner1.   

Abstract

Oncogenic or tumor-induced osteomalacia-rickets is a syndrome characterized by hypophosphatemia, renal phosphate wasting, and decreased serum 1,25-dihydroxyvitamin D3 levels. The tumors secrete a phosphaturic substance that causes total body phosphate depletion, leading to osteomalacia or rickets. Although the tumors are histologically polymorphous, personal review of 16 tumors documented to cause this syndrome revealed four morphologic patterns. The first contained 10 unique-appearing, mixed connective tissue tumors having variably prominent vessels, osteoclastlike giant cells, focal microcystic changes, dystrophic calcification, osseous metaplasia, and/or poorly developed cartilagelike areas. With one exception, all tumors of this group occurred in soft tissue and were benign. The single malignant tumor originated in bone, recurred locally, and metastasized to lung. The remaining tumors occurred in bone and showed benign clinical behavior. They resembled tumors known to occur in bone, that is osteoblastomalike (3 tumors), nonossifying fibromalike (2 tumors), and ossifying fibromalike (1 tumor).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1755097     DOI: 10.3109/01913129109016242

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  20 in total

Review 1.  Tumor-induced osteomalacia.

Authors:  William H Chong; Alfredo A Molinolo; Clara C Chen; Michael T Collins
Journal:  Endocr Relat Cancer       Date:  2011-06-08       Impact factor: 5.678

2.  Phosphaturic mesenchymal tumor with chondromyxoid fibroma-like feature: an unusual morphological appearance.

Authors:  Pallavi Suryawanshi; Manish Agarwal; Rahul Dhake; Saral Desai; Bharat Rekhi; Kishor B Reddy; Nirmala Ajit Jambhekar
Journal:  Skeletal Radiol       Date:  2011-05-01       Impact factor: 2.199

Review 3.  Hypophosphatemic rickets: lessons from disrupted FGF23 control of phosphorus homeostasis.

Authors:  Bracha K Goldsweig; Thomas O Carpenter
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

4.  Striking pathology gold: a singular experience with daily reverberations: sinonasal hemangiopericytoma (glomangiopericytoma) and oncogenic osteomalacia.

Authors:  Margaret Brandwein-Gensler; Gene P Siegal
Journal:  Head Neck Pathol       Date:  2012-03-20

Review 5.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

6.  Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.

Authors:  J C Horng; E Van Eperen; S Tutton; R Singh; J L Shaker; A N Wooldridge
Journal:  Osteoporos Int       Date:  2021-03-02       Impact factor: 4.507

7.  Phosphaturic mesenchymal tumor (mixed connective tissue variant): a case report with spectral analysis.

Authors:  Ksenya V Shelekhova; Dmitry V Kazakov; Ondrej Hes; Vladislav Treska; Michal Michal
Journal:  Virchows Arch       Date:  2006-01-31       Impact factor: 4.064

8.  Varied presentation of sinonasal phosphaturic mesenchymal tumour: report of a case series with follow-up.

Authors:  Regi Kurien; Vedantam Rupa; Meera Thomas
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-16       Impact factor: 2.503

Review 9.  Tumour-induced rickets: a case report and review of the literature.

Authors:  B Eyskens; W Proesmans; B Van Damme; L Lateur; R Bouillon; M Hoogmartens
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.